These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15008033)

  • 21. Medication Adherence Affects Risk of New Diabetes Complications: A Cohort Study.
    Simpson SH; Lin M; Eurich DT
    Ann Pharmacother; 2016 Sep; 50(9):741-6. PubMed ID: 27307411
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of type 2 diabetes mellitus.
    Feinglos MN; Bethel MA
    Med Clin North Am; 1998 Jul; 82(4):757-90. PubMed ID: 9706120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type II diabetes mellitus.
    Edelman SV
    Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy.
    Bell DS
    Clin Ther; 2004 Nov; 26(11):1714-27. PubMed ID: 15639686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed-dose combination therapies in the management of hyperglycaemia in Type 2 diabetes: an opportunity to improve adherence and patient care.
    Schernthaner G
    Diabet Med; 2010 Jul; 27(7):739-43. PubMed ID: 20636953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Humalog Mix 25 in patients with type 2 diabetes which do not achieve acceptable glycemic control with oral agents: results from a phase III, randomized, parallel study.
    Tîrgovişte CI; Străchinariu R; Farcaşiu E; Milicevic Z; Teodorescu G
    Rom J Intern Med; 2003; 41(2):153-62. PubMed ID: 15526500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
    Blonde L; Baker DE; Davis SN; Ratner RE
    J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.
    Hauber AB; Mohamed AF; Johnson FR; Falvey H
    Diabet Med; 2009 Apr; 26(4):416-24. PubMed ID: 19388973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SMS reminders improve adherence to oral medication in type 2 diabetes patients who are real time electronically monitored.
    Vervloet M; van Dijk L; Santen-Reestman J; van Vlijmen B; van Wingerden P; Bouvy ML; de Bakker DH
    Int J Med Inform; 2012 Sep; 81(9):594-604. PubMed ID: 22652012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pen devices to improve patient adherence with insulin therapy in type 2 diabetes.
    Goldstein HH
    Postgrad Med; 2008 Sep; 120(3):172-9. PubMed ID: 18824835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.
    Bode B; Amin A
    Hosp Pract (1995); 2009 Dec; 37(1):7-21. PubMed ID: 20720383
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefits and risks of transfer from oral agents to insulin in type 2 diabetes mellitus.
    Evans A; Krentz AJ
    Drug Saf; 1999 Jul; 21(1):7-22. PubMed ID: 10433350
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term maintenance of glucose control in veterans with type 2 diabetes mellitus using oral agents.
    Swislocki AL; Meier JL; Najera SM; Noth RH
    Metab Syndr Relat Disord; 2011 Dec; 9(6):469-73. PubMed ID: 21864034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes.
    Nadeau DA
    Postgrad Med; 2010 May; 122(3):7-15. PubMed ID: 20463409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The elderly and diabetes: an age trend and an epidemic converging.
    Marquess JG
    Consult Pharm; 2008 Apr; 23 Suppl B():5-11. PubMed ID: 18540787
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of type 2 diabetes: oral agents, insulin, and injectables.
    Fonseca VA; Kulkarni KD
    J Am Diet Assoc; 2008 Apr; 108(4 Suppl 1):S29-33. PubMed ID: 18358251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical impact of oral antidiabetic medications in heart failure patients.
    Palazzuoli A; Ceccarelli E; Ruocco G; Nuti R
    Heart Fail Rev; 2018 May; 23(3):325-335. PubMed ID: 29359260
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes.
    Tanenberg RJ
    Curr Med Res Opin; 2004 Apr; 20(4):541-53. PubMed ID: 15119992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study.
    Donnan PT; MacDonald TM; Morris AD
    Diabet Med; 2002 Apr; 19(4):279-84. PubMed ID: 11942998
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.